Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Zacks Small Cap Research on MSN3h
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...
A patient drive for those who may qualify for medical cannabis or those simply seeking information will take place on ...
For 21 years, Sebastien Beauzile lived with the chronic pain of sickle cell anemia. Now, thanks to a groundbreaking genetic ...
Dominic, 26, fell ill during the second wave of the pandemic in late 2020, and was in intensive care for three months.
Direct-to-patient companies are bringing much-needed disruption to the current healthcare system, challenging payers, ...
Biotech company Valo Health and AI healthcare firm nference have entered into a multi-year partnership to leverage AI and patient data in drug discovery and development. The collaboration will ...
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback